Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension

Summary

This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of escitalopram (30 mg/day) in two parallel groups (randomization ratio, escitalopram 2/placebo 1).

Timeline

Start

2005-06

Primary completion

2008-12

Completion

2008-12

Drugs

Indications